Literature DB >> 21609746

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.

Sonsoles Sánchez-Palomino1, Marta Massanella, Jorge Carrillo, Ana García, Felipe García, Nuria González, Alberto Merino, José Alcamí, Margarita Bofill, Eloísa Yuste, Josep M Gatell, Bonaventura Clotet, Julià Blanco.   

Abstract

BACKGROUND: Cell-to-cell HIV spread through virological synapses proceeds in two steps, first HIV particles are rapidly transferred to target cells in a CD4-dependent manner and then coreceptor-dependent events allow for infection or death of single target cells and cell-to-cell fusion.
METHODS: 293T or MOLT cells producing HIV particles were cocultured with primary CD4 T-cells or reporter cell lines. The extent of HIV transfer, cell fusion and target cell death was assessed. Inhibition by sera from 19 HIV-infected patients was evaluated and compared with cell-free HIV neutralization using different envelopes from clades A, B, C and E.
RESULTS: Sera showed different abilities to protect CD4 T-cells from cell-to-cell transfer, fusion or death when cocultured with HIV producing 293T cells. Some sera were able to block all parameters (a property of IgGb12), while other showed lower activity against HIV transfer despite being able to block fusion and death (a property of antibodies blocking post-CD4 binding steps). Neutralization of cell-to-cell HIV transfer strongly correlated with IgG binding to native Env. Interestingly, sera that efficiently blocked HIV transfer showed broader neutralizing response, as they neutralized a higher percentage of the viruses tested compared with sera showing low CD4 binding site responses (P=0.01). Similar results were observed in a model of T cell-T cell HIV transmission, although this experimental model showed lower capacity to discriminate broadly neutralizing responses.
CONCLUSION: Cell-to-cell HIV transfer assays identify sera with broadly neutralizing capacity and may help to characterize anti-HIV humoral responses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609746     DOI: 10.1016/j.vaccine.2011.05.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Measuring T Cell-to-T Cell HIV-1 Transfer, Viral Fusion, and Infection Using Flow Cytometry.

Authors:  Natasha D Durham; Benjamin K Chen
Journal:  Methods Mol Biol       Date:  2016

2.  Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.

Authors:  Natasha D Durham; Alice W Yewdall; Ping Chen; Rebecca Lee; Chati Zony; James E Robinson; Benjamin K Chen
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

3.  Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.

Authors:  Edwards Pradenas; Maria Ubals; Víctor Urrea; Clara Suñer; Benjamin Trinité; Eva Riveira-Muñoz; Silvia Marfil; Carlos Ávila-Nieto; María Luisa Rodríguez de la Concepción; Ferran Tarrés-Freixas; Josep Laporte; Ester Ballana; Jorge Carrillo; Bonaventura Clotet; Oriol Mitjà; Julià Blanco
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

4.  Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.

Authors:  Anuska Llano; Jorge Carrillo; Beatriz Mothe; Lidia Ruiz; Silvia Marfil; Elisabet García; Eloísa Yuste; Víctor Sánchez; Bonaventura Clotet; Julià Blanco; Christian Brander
Journal:  J Transl Med       Date:  2013-02-22       Impact factor: 5.531

5.  Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.

Authors:  Luis M Molinos-Albert; Jorge Carrillo; Marta Curriu; Maria L Rodriguez de la Concepción; Silvia Marfil; Elisabet García; Bonaventura Clotet; Julià Blanco
Journal:  Retrovirology       Date:  2014-06-07       Impact factor: 4.602

6.  Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals.

Authors:  Jorge Carrillo; Luis Manuel Molinos-Albert; Maria Luisa Rodríguez de la Concepción; Silvia Marfil; Elisabet García; Ronald Derking; Rogier W Sanders; Bonaventura Clotet; Julià Blanco
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

7.  Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Authors:  Luis M Molinos-Albert; Eneritz Bilbao; Luis Agulló; Silvia Marfil; Elisabet García; Maria Luisa Rodríguez de la Concepción; Nuria Izquierdo-Useros; Cristina Vilaplana; Jon A Nieto-Garai; F-Xabier Contreras; Martin Floor; Pere J Cardona; Javier Martinez-Picado; Bonaventura Clotet; Jordi Villà-Freixa; Maier Lorizate; Jorge Carrillo; Julià Blanco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 8.  Non-Neutralizing Antibodies Directed against HIV and Their Functions.

Authors:  Luzia M Mayr; Bin Su; Christiane Moog
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

9.  Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.

Authors:  Benjamin Trinité; Edwards Pradenas; Silvia Marfil; Carla Rovirosa; Víctor Urrea; Ferran Tarrés-Freixas; Raquel Ortiz; Jordi Rodon; Júlia Vergara-Alert; Joaquim Segalés; Victor Guallar; Rosalba Lepore; Nuria Izquierdo-Useros; Glòria Trujillo; Jaume Trapé; Carolina González-Fernández; Antonia Flor; Rafel Pérez-Vidal; Ruth Toledo; Anna Chamorro; Roger Paredes; Ignacio Blanco; Eulàlia Grau; Marta Massanella; Jorge Carrillo; Bonaventura Clotet; Julià Blanco
Journal:  Viruses       Date:  2021-06-12       Impact factor: 5.048

Review 10.  Which Antibody Functions are Important for an HIV Vaccine?

Authors:  Bin Su; Christiane Moog
Journal:  Front Immunol       Date:  2014-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.